FASN and metabolic dysfunction-associated steatotic liver disease: Dorn et al. indicated that fatty acid synthase may serve as a therapeutic target for the progression of NAFLD [36], suggesting that the pathway of fatty acid biosynthesis plays an important role in the pathogenesis of NAFLD.